Search results
Found 1056 matches for
A new treatment targeting tenascin-C could reduce the progression and severity of rheumatoid arthritis (RA) at the very early stages of disease.
Trials Expertise Session: The role of a Trial Manager in a Trial Management Group (TMG) *online*
Thursday, 12 June 2025, 10am to 11am
Trials Expertise Session: Communication skills in Clinical Trials for Trial Managers *online*
Wednesday, 26 March 2025, 10am to 11am
Trials Expertise Session: Site Feasibility Questionnaires (SFQ) & Site selection *Hybrid*
Wednesday, 25 June 2025, 11am to 12pm
Meet the team
-
Kim Midwood
Kennedy Director of Graduate Studies
-
Anja Schwenzer
Postdoctoral Research Assistant
-
Felix Clanchy
Senior Postdoctoral Researcher
-
Richard Williams
Professor
-
Christopher Buckley
Kennedy Professor of Translational Rheumatology and Director of Clinical Research
Read the articles
Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?
Annals of the Rheumatic Diseases 2019;78:186-191.
Annals of the Rheumatic Diseases Published Online First: 12 February 2019. doi: 10.1136/annrheumdis-2019-215108
Extracellular matrix in the crosshairs, Collison J
Nature Reviews Rheumatologyvolume 15, page65 (2019)
Supported by
This work was supported by grants from Nascient Ltd and Versus Arthritis. This work was also supported by the Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence and by the Kennedy Trust for Rheumatology Research. This report includes independent research supported by the National Institute for Health Research/Wellcome Trust Clinical Research Facility at University Hospitals Birmingham NHS Foundation Trust.